Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee

Sarah Cannon Research Institute (SCRI) Oncology Partners is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Health Trust Score: 73/100 (FAIR). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute (SCRI) Oncology Partners has participated in 6 clinical trials with 6 currently active.

Therapeutic areas: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Advanced Solid Tumor.

Sponsors: Acepodia Biotech, Inc., Clasp Therapeutics, Inc., Regeneron Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 73/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute (SCRI) Oncology Partners?

Sarah Cannon Research Institute (SCRI) Oncology Partners has a Crixeo Trust Score of 73/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute (SCRI) Oncology Partners conducted?

Sarah Cannon Research Institute (SCRI) Oncology Partners has 6 clinical trials on record, with 6 currently active. Their work covers Locally Advanced Solid Tumor, Metastatic Solid Tumor, Advanced Solid Tumor.

Is Sarah Cannon Research Institute (SCRI) Oncology Partners accredited by Crixeo Health?

Yes — Sarah Cannon Research Institute (SCRI) Oncology Partners holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Sarah Cannon Research Institute (SCRI) Oncology Partners?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.